Medivation

Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim
Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim
Endpoints
Pfizer
Xtandi
Talzenna
PARP inhibitors
Medivation
clinical trials
prostate cancer
Flag link:
5 years after Pfizer buyout, SEC charges Medivation's ex-dealmaking lead with insider trading
5 years after Pfizer buyout, SEC charges Medivation's ex-dealmaking lead with insider trading
Fierce Pharma
Medivation
Pfizer
M&A
SEC
insider trading
Flag link:
Can This Pharma's $14 Billion Bet Succeed?
Can This Pharma's $14 Billion Bet Succeed?
Motley Fool
Pfizer
M&A
Medivation
Xtandi
talazoparib
Flag link:
The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer’s drug
The billion-dollar gamble: Biotech CEO takes a risky second shot at an Alzheimer’s drug
Stat
Alzheimer's disease
Axovant
David Hung
dimebon
Medivation
intepirdine
Flag link:
The top 15 highest-paid biopharma executives
The top 15 highest-paid biopharma executives
Fierce Pharma
executive pay
Mylan Labs
Valeant Pharmaceuticals
Medivation
Regeneron
JNJ
Merck
Flag link:
Pfizer's $14B Medivation deal's now a cautionary M&A tale, thanks to ASCO: analyst
Pfizer's $14B Medivation deal's now a cautionary M&A tale, thanks to ASCO: analyst
Fierce Pharma
Pfizer
Medivation
M&A
ASCO 2017
Flag link:
With Pfizer’s Xtandi sales slowing, analysts question $14B Medivation price
With Pfizer’s Xtandi sales slowing, analysts question $14B Medivation price
Fierce Pharma
Pfizer
Xtandi
Medivation
Flag link:
About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet
About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet
Fierce Pharma
M&A
Stada
Shire
Baxalta
JNJ
Actelion
Mylan Labs
Pfizer
Takeda
Ariad Pharmaceuticals
Medivation
Flag link:
2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals
2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals
Endpoints
M&A
Shire
Baxalta
Pfizer
Medivation
Mylan
Meda
AbbVie
Stemcentrx
Anacor
Flag link:
The Best Biopharma CEOs of 2016 Are...
The Best Biopharma CEOs of 2016 Are...
TheStreet.com
Pharma CEOs
Ken Frazier
Merck
David Hung
Medivation
Scott Jackson
Celator Pharmaceuticals
Ed Kaye
Sarepta Therapeutics
Mike Morrissey
Exelixis
Flag link:
What Happened in Biotech in 2016?
What Happened in Biotech in 2016?
Motley Fool
biotech
M&A
biosimilars
IPOs
Editas Medicine
CRISPR Therapeutics
Pfizer
Medivation
Celgene
Juno Therapeutics
Sarepta Therapeutics
Flag link:
Key FDA Decisions and Trial Results Expected in October
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
FDA
clinical trials
Exelixis
cabozantinib
Cobimetinib
Celldex Therapeutics
CDX-011
Cerulean Pharma
CRLX101
Medivation
Xtandi
Palatin
bermelanotide
Rexahn
RX-3117
Anthera Pharmaceuticals
Flag link:
A Look at the Pfizer-Medivation Deal
A Look at the Pfizer-Medivation Deal
Market Realist
Pfizer
Medivation
M&A
Flag link:
Pfizer Completes Acquisition of Medivation
Pfizer Completes Acquisition of Medivation
Yahoo
Pfizer
Medivation
M&A
Flag link:
Is This Pfizer's Next Mega-Blockbuster Cancer Drug?
Is This Pfizer's Next Mega-Blockbuster Cancer Drug?
Motley Fool
Pfizer
Medivation
Xtandi
avelumab
Merck KGaA
Ibrance
Flag link:
Pfizer: Hospira Is Future; Xtandi Is Today's Meal
Pfizer: Hospira Is Future; Xtandi Is Today's Meal
Yahoo/GuruFocus
Pfizer
Hospira
Xtandi
M&A
Medivation
Flag link:
After Losing Medivation, Who Is Gilead Going After Next?
After Losing Medivation, Who Is Gilead Going After Next?
Forbes
Medivation
Gilead Sciences
M&A
Puma Biotechnology
Kite Pharma
Incyte
Portola Pharmaceuticals
Flag link:
Key FDA Decisions and Trial Results Coming in the Next 2 Months
Key FDA Decisions and Trial Results Coming in the Next 2 Months
24/7 Wall St
FDA
clinical trials
Array Biopharma
binimetinib
Mast Therapeutics
Novavax
RSV F vaccine
Threshold Pharmaceuticals
tarloxotinib
Cerulean Pharma
Vertex Pharmaceuticals
Orkambi
Exelixis
cabozantinib
Cobimetinib
Medivation
Xtandi
Celldex
Flag link:
Key FDA Decisions and Trial Results Expected in October
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
FDA
clinical trials
cabozantinib
Cobimetinib
Exelixis
Medivation
Xtandi
Celldex Therapeutics
glemba
Palatin
bremelanotide
CRLX101
Cerulean Pharma
Anthera Pharmaceuticals
Flag link:
How did Pfizer swat off rival Medivation bidders? Price, yes, but a CEO confab helped
How did Pfizer swat off rival Medivation bidders? Price, yes, but a CEO confab helped
Fierce Pharma
Pfizer
Medivation
M&A
Pharma CEOs
Flag link:

Pages